Suppr超能文献

实体器官移植患者中FK506诱导高血压的分子机制

Molecular mechanisms of FK506-induced hypertension in solid organ transplantation patients.

作者信息

Wang Jianglin, Guo Ren, Liu Shikun, Chen Qingjie, Zuo Shanru, Yang Meng, Zuo Xiaocong

机构信息

Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China.

Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, China. Email:

出版信息

Chin Med J (Engl). 2014;127(20):3645-50.

Abstract

OBJECTIVE

Tacrolimus (FK506) is an immunosuppressive drug, which is widely used to prevent rejection of transplanted organs. However, chronic administration of FK506 leads to hypertension in solid organ transplantation patients, and its molecular mechanisms are much more complicated. In this review, we will discuss the above-mentioned molecular mechanisms of FK506-induced hypertension in solid organ transplantation subjects.

DATA SOURCES

The data analyzed in this review were mainly from relevant articles without restriction on the publication date reported in PubMed. The terms "FK506" or "tacrolimus" and "hypertension" were used for the literature search.

STUDY SELECTION

Original articles with no limitation of research design and critical reviews containing data relevant to FK506-induced hypertension and its molecular mechanisms were retrieved, reviewed and analyzed.

RESULTS

There are several molecular mechanisms attributed to FK506-induced hypertension in solid organ transplantation subjects. First, FK506 binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and removes them from intracellular ryanodine receptors that induce a calcium ion leakage from the endoplasmic/sarcoplasmic reticulum. The conventional protein kinase C beta II (cPKCβII)-mediated phosphorylation of endothelial nitric oxide (NO) synthase at Thr495, which reduces the production of NO, was activated by calcium ion leakage. Second, transforming growth factor receptor/SMAD2/3 signaling activation plays an important role in Treg/Th17 cell imbalance in T cells which toget converge to cause inflammation, endothelial dysfunction, and hypertension following tacrolimus treatment. Third, the activation of with-no-K(Lys) kinases/STE20/SPS1-related proline/alanine-rich kinase/thiazide-sensitive sodium chloride co-transporter (WNKs/SPAK/NCC) pathway has a central role in tacrolimus-induced hypertension. Finally, the enhanced activity of renal renin-angiotensin-aldosterone system seems to play a crucial role in the pathophysiology of FK506-induced hypertension.

CONCLUSION

FK506 plays a predominant role in the pathophysiology of hypertension in solid organ transplantation subjects.

摘要

目的

他克莫司(FK506)是一种免疫抑制药物,广泛用于预防移植器官的排斥反应。然而,长期使用FK506会导致实体器官移植患者出现高血压,其分子机制更为复杂。在本综述中,我们将讨论上述FK506诱导实体器官移植受者高血压的分子机制。

数据来源

本综述分析的数据主要来自PubMed报道的对发表日期无限制的相关文章。使用“FK506”或“他克莫司”以及“高血压”等术语进行文献检索。

研究选择

检索、回顾和分析了无研究设计限制的原始文章以及包含与FK506诱导的高血压及其分子机制相关数据的综述。

结果

实体器官移植受者中,FK506诱导高血压存在多种分子机制。首先,FK506与FK506结合蛋白12及其相关异构体12.6(FKBP12/12.6)结合,并将它们从细胞内的兰尼碱受体上移除,从而导致内质网/肌浆网钙离子泄漏。钙离子泄漏激活了传统蛋白激酶CβII(cPKCβII)介导的内皮型一氧化氮合酶在苏氨酸495位点的磷酸化,这减少了一氧化氮的产生。其次,转化生长因子受体/SMAD2/3信号激活在T细胞的调节性T细胞/辅助性T细胞17失衡中起重要作用,这共同导致他克莫司治疗后出现炎症、内皮功能障碍和高血压。第三,无赖氨酸(Lys)激酶/STE20/SPS1相关脯氨酸/丙氨酸丰富激酶/噻嗪敏感的氯化钠共转运体(WNKs/SPAK/NCC)途径的激活在他克莫司诱导的高血压中起核心作用。最后,肾素 - 血管紧张素 - 醛固酮系统活性增强似乎在FK506诱导的高血压病理生理过程中起关键作用。

结论

FK506在实体器官移植受者高血压的病理生理过程中起主要作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验